Topics

Latest "Roche Tecentriq gets another" News Stories

15:59 EST 20th February 2020 | BioPortfolio

Here are the most relevant search results for "Roche Tecentriq gets another" found in our extensive news archives from over 250 global news sources.

More Information about Roche Tecentriq gets another on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Roche Tecentriq gets another for you to read. Along with our medical data and news we also list Roche Tecentriq gets another Clinical Trials, which are updated daily. BioPortfolio also has a large database of Roche Tecentriq gets another Companies for you to search.

Showing "Roche Tecentriq gets another" News Articles 1–25 of 1,900+

Thursday 20th February 2020

20172025 World Antibody Market Research Report by Product Type, EndUser / Application and Regions / Countries [Published by HeyReport] Prices from USD $2380

SummaryIn Vitro Diagnostics IVD are tests used to detect disease, infections and other medical conditions. IVD antibodies are widely used for immunology methods such as immunonephelometry and sandwich ELISA.This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and en...


Ten billion investment to build Chengdu medical city to create a new highland for the international health industry

CHENGDU, China, Feb. 20, 2020 /PRNewswire/ -- In 2019, with the continuous advancement of "three medical integration", Chengdu Medical City's three medical innovation center, as "Western China Biomedical Innovation Center", submitted a satisfactory answer sheet: 58 new contracted projects (47 three medical projects, and 10 projects worth more than 500 million yuan), total inves...

Roche’s Tecentriq gets US priority review for lung cancer

The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics license application (sBLA) of Tecentriq...Read More... The post Roche’s Tecentriq gets US priority review for lung cancer appeared first on Pharmaceutical Technology.


FDA grants priority review to Genentech’s Tecentriq as first-line treatment of certain people with advanced NSCLC

The FDA is expected to make a decision on approval by June 19, 2020. “In the IMpower110 study, Tecentriq alone demonstrated a significant improvement in overall survival compared The post FDA grants priority review to Genentech’s Tecentriq as first-line treatment of certain people with advanced NSCLC appeared first on Pharmaceutical Business review.

Roche’s Tecentriq bags Priority Review in US

In a trial, the drug improved overall survival by 7.1 months compared with chemotherapy.

Roche stellt neuen Service für Diabetes-Patienten an Fachmesse vor

Basel (awp) - Roche will Diabetes-Patienten das Leben künftig mit RocheDiabetes InsulinStart erleichtern. Dabei handelt es sich um einen Service, der vor allem den Übergang von oralen Antidiabetika...

Roche präsentiert RocheDiabetes InsulinStart, einen neuen Service zur Erleichterung des Einstiegs in die Insulintherapie

Madrid (ots/PRNewswire) - -- RocheDiabetes InsulinStart ist ein Service für Menschen mit Typ-2-Diabetes, der den Übergang von oralen Antidiabetika auf eine ergänzende, lang wirkende Insulintherapie...

Roche presents RocheDiabetes InsulinStart, a new service for an easy start to insulin therapy

-- RocheDiabetes InsulinStart is a service designed for people with type 2 diabetes to ease the transition from oral antidiabetics to a complementary long-acting insulin therapy. -- By using prove...

Vantage 2019 Review: Standout Year for Pharma, Anchored by Strong Fourth Quarter Markets and Dealmaking

Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of 2018. Over the course of the year, several major biopharma companies showed double-digit share price growth, drug makers spent $217bn on M&A deals and 55 companies floated on Western exchanges. AstraZeneca’s 31% inc...

Wednesday 19th February 2020

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half...    

FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-Line Treatment for Certain People with Advanced NSCLC

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanced non-squa...

Biotech company Promedior merges with Roche

Roche has successfully completed its purchase of Promedior, Inc. along with its entire portfolio of fibrotic disease therapeutics. The post Biotech company Promedior merges with Roche appeared first on European Pharmaceutical Review.

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong...   

China approves Roche's Tecentriq-chemo combo for SCLC

China's National Medical Products Administration has approved Roche's drug Tecentriq, or atezolizumab, which will be used in  -More- 

FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review

Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first   

FDA sets June decision date for Tecentriq monotherapy in NSCLC

Aims for the first-line setting where Merck's Keytruda dominates

Great article for @GENbio from @DrSuePearson on recent advancements in the #LabOfTheFuture https://snip.ly/0tenr1  #BioTech #SmartLab #DigitalLabAssistant #DigitalTransformation #LabDigitization #AI #Biotech @GENbio @Roche @AstraZeneca @JanssenGlobal @G

Great article for @GENbio from @DrSuePearson on recent advancements in the #LabOfTheFuture https://snip.ly/0tenr1  #BioTech #SmartLab #DigitalLabAssistant

FDA grants priority review to Roche's filing seeking approval of Tecentriq as first-line treatment for certain people with advanced NSCLC https://www.firstwordpharma.com/node/1701919  $RHHBY

FDA grants priority review to Roche's filing seeking approval of Tecentriq as first-line treatment for certain people with advanced NSCLC https://www.firstwordpharma.com/node/1701919  $RHHBY

FDA grants priority review to Roche's Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without

Roche erhält von FDA für Tecentriq bei Lungenkrebs vorrangige Prüfung

Wie der Konzern am Mittwoch mitteilte, hat die Behörde dem Antrag den Status "Priority Review" gewährt.Mit diesem Status verkürzt sich die Zeit, in der die Behörde die Zulassung überprüft. Im Fall ...

Genentech Says FDA Grants Priority Review To Tecentriq Monotherapy

Genentech, a member of Swiss drug maker Roche Group (RHHBY) said Wednesday that the U.S. Food and Drug Administration or FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as a first-line monotherapy for certain people with advanced non-small cell lung cancer.

F. Hoffmann-La Roche Ltd: FDA grants priority review to Roche's Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer

Basel, 19 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sB...

FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer (NSCLC)...

FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer

Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR...

Tuesday 18th February 2020

FDA Grants Priority Review to Atezolizumab to Treat Advanced Non-Small Cell Lung Cancer

Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.


Quick Search

News Quicklinks